Merck & Co. is investing in new products and research to sustain growth as its key cancer drug, KEYTRUDA, nears loss of market exclusivity. Despite a recent 1.91% daily stock drop to $144.71, Merck's shares gained nearly 11% over the past month, outperforming the broader market. Analyst Luisa Hector set a price target of $137, below the current price, signaling cautious investor outlook. Investors await Merck's upcoming financial report, with earnings expected at $2.27 per share and revenue forecasted to rise 1.94% to $17.61 billion.
Jefferies has lowered its peak sales forecast for Merck's experimental eye drug remigromig by 60%, citing trial results that showed it was less effective and had more safety issues than the established treatment Lucentis. The drug met non-inferiority...
AbbVie’s stock trades near $277, close to a $279 price target, driven by strong growth in drugs Skyrizi and Rinvoq, and recent FDA approvals including JUVMO for Parkinson’s. The company’s acquisition of Apogee Therapeutics and raised revenue guidance...
